Ischemiamodified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease

Background/Aims: The achievement of endoscopic remission is an important therapeutic goal in the treatment of inflamma-tory bowel diseases (IBD). We aimed to evaluate the role of fecal calprotectin (FCP) and ischemia-modified albumin (IMA) as biomarkers for evaluating IBD disease activity. Methods: A total of 48 patients with IBD (20 with ulcerative colitis and 28 with Crohn's disease) were included in this study. FCP and serum C -reactive protein levels, erythrocyte sedimentation rate, and IMA were measured in patients with IBD and compared with endoscopic findings. Results: Elevated FCP and serum IMA levels were significantly associated with endoscopic non-mucosal healing. The correlation between FCP and IMA was not significant. Analysis of the receiver operating characteristic curve showed that both FCP and IMA had diagnostic value in predicting non- mucosal healing. When the Ln(FCP)+IMA/10 value was calculated using both factors, the predictive value for non-mucosal healing increased; however, no significant difference was observed. Conclusions: IMA could be a candidate serum biomarker for predicting endoscopic mucosal healing in IBD. (Intest Res, Published online )